Detalles de la búsqueda
1.
Influence of platelet count at diagnosis and during the course of disease on prognosis in MDS patients.
Ann Hematol
; 100(10): 2575-2584, 2021 Oct.
Artículo
en Inglés
| MEDLINE | ID: mdl-34324021
2.
Treatment of myeloid malignancies relapsing after allogeneic hematopoietic stem cell transplantation with venetoclax and hypomethylating agents-a retrospective multicenter analysis on behalf of the German Cooperative Transplant Study Group.
Ann Hematol
; 100(4): 959-968, 2021 Apr.
Artículo
en Inglés
| MEDLINE | ID: mdl-33191481
3.
Prognostic impact of pretransplant measurable residual disease assessed by peripheral blood WT1-mRNA expression in patients with AML and MDS.
Eur J Haematol
; 107(2): 283-292, 2021 Aug.
Artículo
en Inglés
| MEDLINE | ID: mdl-33987857
4.
Spontaneous remission in a patient with very late relapse of acute myeloid leukemia 17 years after allogeneic blood stem cell transplantation.
Eur J Haematol
; 103(2): 131-133, 2019 Aug.
Artículo
en Inglés
| MEDLINE | ID: mdl-31066931
5.
Cytogenetic clonal evolution in myelodysplastic syndromes is associated with inferior prognosis.
Cancer
; 123(23): 4608-4616, 2017 Dec 01.
Artículo
en Inglés
| MEDLINE | ID: mdl-28746789
6.
Correction to: Treatment of myeloid malignancies relapsing after allogeneic hematopoietic stem cell transplantation with venetoclax and hypomethylating agents-a retrospective multicenter analysis on behalf of the German Cooperative Transplant Study Group.
Ann Hematol
; 100(8): 2141-2142, 2021 Aug.
Artículo
en Inglés
| MEDLINE | ID: mdl-34160650
7.
Allogeneic Hematopoietic Cell Transplantation in Advanced Systemic Mastocytosis: A retrospective analysis of the DRST and GREM registries.
Leukemia
; 38(4): 810-821, 2024 Apr.
Artículo
en Inglés
| MEDLINE | ID: mdl-38448757
8.
Allogeneic hematopoietic stem cell transplantation and pre-transplant strategies in patients with NPM1-mutated acute myeloid leukemia: a single center experience.
Sci Rep
; 13(1): 10774, 2023 07 04.
Artículo
en Inglés
| MEDLINE | ID: mdl-37402862
9.
Clinical and Cytogenetic Characterization of Early and Late Relapses in Patients Allografted for Myeloid Neoplasms with a Myelodysplastic Component.
Cancers (Basel)
; 14(24)2022 Dec 18.
Artículo
en Inglés
| MEDLINE | ID: mdl-36551729
10.
Feasibility of Wearable-Based Remote Monitoring in Patients During Intensive Treatment for Aggressive Hematologic Malignancies.
JCO Clin Cancer Inform
; 6: e2100126, 2022 01.
Artículo
en Inglés
| MEDLINE | ID: mdl-35025669
11.
Guidelines for Myelodysplastic Syndromes: Converting Evidence into Action?
Int J Environ Res Public Health
; 18(14)2021 07 18.
Artículo
en Inglés
| MEDLINE | ID: mdl-34300079
12.
Eligibility for clinical trials is unsatisfactory for patients with myelodysplastic syndromes, even at a tertiary referral center.
Leuk Res
; 108: 106611, 2021 09.
Artículo
en Inglés
| MEDLINE | ID: mdl-33990002
13.
Outcomes of patients with chronic myelomonocytic leukaemia treated with non-curative therapies: a retrospective cohort study.
Lancet Haematol
; 8(2): e135-e148, 2021 Feb.
Artículo
en Inglés
| MEDLINE | ID: mdl-33513373
14.
Improving the accuracy of prognostication in chronic myelomonocytic leukemia.
Expert Rev Anticancer Ther
; 20(8): 703-714, 2020 08.
Artículo
en Inglés
| MEDLINE | ID: mdl-32700646
15.
Prediction of Response and Survival Following Treatment with Azacitidine for Relapse of Acute Myeloid Leukemia and Myelodysplastic Syndromes after Allogeneic Hematopoietic Stem Cell Transplantation.
Cancers (Basel)
; 12(8)2020 Aug 12.
Artículo
en Inglés
| MEDLINE | ID: mdl-32806572
16.
Molecular genetics in allogeneic blood stem cell transplantation for myelodysplastic syndromes.
Expert Rev Hematol
; 12(10): 821-831, 2019 10.
Artículo
en Inglés
| MEDLINE | ID: mdl-31322458
17.
Novel therapies in low- and high-risk myelodysplastic syndrome.
Expert Rev Hematol
; 12(10): 893-908, 2019 10.
Artículo
en Inglés
| MEDLINE | ID: mdl-31353975
18.
Lymphopenia at diagnosis is highly prevalent in myelodysplastic syndromes and has an independent negative prognostic value in IPSS-R-low-risk patients.
Blood Cancer J
; 9(8): 63, 2019 08 09.
Artículo
en Inglés
| MEDLINE | ID: mdl-31399557
19.
EASIX for prediction of survival in lower-risk myelodysplastic syndromes.
Blood Cancer J
; 9(11): 85, 2019 11 11.
Artículo
en Inglés
| MEDLINE | ID: mdl-31712595
20.
Outcome of Lower-Risk Patients With Myelodysplastic Syndromes Without 5q Deletion After Failure of Erythropoiesis-Stimulating Agents.
J Clin Oncol
; 35(14): 1591-1597, 2017 May 10.
Artículo
en Inglés
| MEDLINE | ID: mdl-28350519